Introduction {#sec1_1}
============

Gastrinoma is a neuroendocrine tumor (NET) that secretes excess amounts of gastrin. It causes peptic ulcer in the duodenum, stomach, and small intestine. The 5-year survival rate of patients with metastatic gastrinoma is reported to be about 20--40% \[[@B1]\].

Somatostatin analogues (SSAs), octreotide and lanreotide, are effective for the management of functional NETs. While SSAs are used to control the symptoms due to release of bioactive amines, such as gastrin, it has been suggested that they have the ability to suppress the growth of advanced NETs.

For the treatment of unresectable NETs, the National Comprehensive Cancer Network (NCCN) guidelines recommend cytotoxic chemotherapy in combination with other treatment methods. Although S-1, an oral fluorinated pyrimidine, is not referred to in the NCCN guidelines, it has an indication for the treatment of a wide variety of gastrointestinal tract neoplasms containing pancreatic cancer in Japan.

Here, we present a patient with metastatic gastrinoma who has shown a good response to S-1 and octreotide for more than 8 years.

Case Presentation {#sec1_2}
=================

In 2008, a 53-year-old woman presented with elevated levels of liver enzymes. Abdominal sonography revealed multiple liver tumors without symptoms. She had a history of duodenal ulcer for 2 years and had received proton pump inhibitor treatment. No particular family history was noted. A computed tomography (CT) scan showed a slightly enhanced pancreatic tail tumor, measuring 53 mm in diameter (Fig. [1a](#F1){ref-type="fig"}). There were prominent multiple metastatic tumors in the liver, which had a maximum diameter of 32 mm (Fig. [1a](#F1){ref-type="fig"}). No abnormal findings were noted in the upper and lower gastrointestinal endoscopic examinations. The clinical staging was T3N0M1 stage IV tumor according to the TNM classification. The Eastern Cooperative Oncology Group (ECOG) performance status was 0. Hormonal evaluation revealed increased levels of gastrin to 450,000 pg/mL (normal range: 30--150 pg/mL), but other pancreatic hormones were not elevated.

Needle biopsy of the liver tumor showed malignant cells proliferating in a trabecular pattern (Fig. [2a](#F2){ref-type="fig"}). Immunohistochemical staining showed that the tumor cells were positive for synaptophysin (Fig. [2b](#F2){ref-type="fig"}), and the Ki-67 index was 29.1% (Fig. [2c](#F2){ref-type="fig"}). Structural atypia was not so remarkable. We made a pathological diagnosis of a well-differentiated endocrine carcinoma according to the 2004 World Health Organization (WHO) classification, which corresponded to intermediate-grade (grade 2) NET based on the 2010 WHO classification. These findings were consistent with grade 2 pancreatic NET (gastrinoma). There were no family history or other accompanying tumors related to multiple endocrine neoplasia type 1 (MEN-1).

She received subcutaneous injections of octreotide at a dose of 50 µg every 12 h; 4 days later, the dose of octreotide was increased to 100 µg every 12 h without side effects. Changes in the serum gastrin levels are shown in Figure [3](#F3){ref-type="fig"}, indicating a significant decrease after the start of octreotide treatment. For convenience, her treatment was changed to 20 mg of long-acting intramuscular octreotide once a month following 200 µg daily injections. In conjunction with octreotide treatment, oral S-1 (40 mg/m^2^ body surface area), was administered twice daily on days 1--28. Administration was repeated every 6 weeks. Regression of the metastatic tumors of liver on enhanced abdominal CT scans is shown in Figure [1](#F1){ref-type="fig"}. After 6 months (4 cycles of chemotherapy with S-1), a CT scan revealed that the diameter of the pancreatic tumor had decreased to 28 mm (Fig. [1b](#F1){ref-type="fig"}). According to the response evaluation criteria in solid tumors (RECIST) version 1.1, we considered that this patient had achieved a partial response. Four years later, we recommended her to have a surgery; however, she did not agree to undergo the surgery and chose to continue with chemotherapy. The patient has showed good response to the treatment for more than 8 years, and she continues to receive S-1 and octreotide therapy. Her gastrin level has decreased to 850 pg/mL, and she remains asymptomatic with no disease progression (Fig. [3](#F3){ref-type="fig"}).

Discussion {#sec1_3}
==========

The 2003 WHO classification subdivides pancreatic gastrinomas into three general categories. About 10--30% of gastrinomas are well-differentiated endocrine tumors, 50--80% of gastrinomas are well-differentiated endocrine carcinomas, and only 1--3% of gastrinomas are poorly differentiated endocrine carcinomas \[[@B1]\]. The 2004 WHO classification used a hybrid of grading (the inherent biologic aggressiveness of the tumor as assessed by histologic features) and staging. According to the 2010 WHO classification, neuroendocrine neoplasms are classified by their proliferative rates. Some reports suggest that NET grade 3 and neuroendocrine carcinomas are heterogeneous, and propose the introduction of a new category of neuroendocrine neoplasms characterized by well-differentiated tumor morphology and MIB-1 index \>20%, named grade 3 well-differentiated NETs \[[@B2]\]. In our case, structural atypia was not remarkable and the MIB-1 index was 29.1%. Our case, therefore, corresponds to grade 3 well-differentiated NETs, and these patients survive longer than those with MIB-1 index \>55% \[[@B2]\].

According to the NCCN guidelines for NETs, octreotide is recommended for patients with metastatic gastrinoma. Furthermore, the management of gastrinoma with unresectable liver metastases includes hepatic regional therapy, cytoreductive surgery, everolimus, sunitinib, and cytotoxic chemotherapy \[[@B1]\].

The antitumor effects of octreotide LAR (long-acting release) were reported in the PROMID study in patients with metastatic neuroendocrine midgut tumors. A significant improvement in median time-to-progression (TTP) from 6 months in the placebo group to 14.3 months in the octreotide LAR group was observed \[[@B3]\]. The CLARINET trial showed that treatment with lanreotide, a long-acting SSA, significantly improved progression-free survival in patients with NETs of both gastrointestinal and pancreatic origins. For this study, all subgroups demonstrated a significant or strong trend toward improved progression-free survival with lanreotide, including midgut and pancreas primaries, grade 1 and 2, and hepatic tumor volume ≤25% or \>25% \[[@B3]\].

Shojamanesh et al. \[[@B4]\] reported that the response rate to octreotide in patients with malignant gastrinoma (rate of tumor regression of more than 25% decrease in tumor size) or tumor stabilization was 53%, and the mean duration of response was 25.0 months. In that study, slow-growing NETs (slow tumor growth was defined as a 1--50% increase in tumor volume per month) responded better to octreotide treatment, and there was a tendency toward longer survival. On the other hand, octreotide monotherapy seems insufficient for rapid-growing NETs (rapid tumor growth was defined as \>50% increase in tumor volume per month). There was a trend of responsiveness to chemotherapy in tumors with high Ki-67 index. As a criterion for selecting patients for cytotoxic treatment, Vilar et al. \[[@B5]\] proposed that the Ki-67 index should be \>10%.

Our case had several characteristics that were considered as unfavorable prognosis, including liver metastases, Ki-67 index \>2, exclusion of MEN-1, markedly increased fasting gastrin levels, presence of a large primary tumor (\>3 cm), a pancreatic primary gastrinoma, and female gender \[[@B1]\]. We considered cytotoxic agents were preferable for the treatment of our patient because of the high Ki-67 index and unfavorable prognosis risk factors.

Previously, a combination of streptozocin and fluorouracil was shown to be effective and safe for the treatment of NETs by several clinical trials \[[@B1]\]. However, when we started the treatment in 2008, streptozocin, a traditionally used cytotoxic drug, was not used in Japan. On the other hand, S-1, an oral fluorinated pyrimidine was indicated for the treatment of pancreatic cancers in Japan. Hence, we decided to administer chemotherapy with S-1 and octreotide. To the best of our knowledge, several patients with pancreatic NETs who were treated with S-1 have been reported in the Japanese and English literature (Table [1](#T1){ref-type="table"}) \[[@B6], [@B7], [@B8], [@B9], [@B10], [@B11], [@B12], [@B13], [@B14], [@B15]\]. S-1 was used as a single agent, as well as in combination therapy. S-1 consists of a combination of drugs such as octreotide, gemcitabine, and streptozocin. The anti-growth effect of S-1 containing chemotherapy varies from partial response to progressive disease by case reports \[[@B6], [@B7], [@B8], [@B9], [@B10], [@B11], [@B12], [@B13], [@B14], [@B15]\].

In our case, good clinical response and marked tumor reduction was achieved by combination therapy with octreotide and S-1, thereby enabling progression-free survival for over 8 years to be achieved. Additionally, this case suggests that combination therapy with octreotide and S-1 can be efficacious and well tolerated in patients with metastatic gastrinoma.
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![Enhanced computed tomography (CT) images before the treatment with S-1 and octreotide showed the pancreatic tumor and multiple liver metastases (**a**). CT images 6 months after the initiation of treatment (**b**), and images taken at 4 years (**c**) and 7 years (**d**) after the initiation of chemotherapy, revealing that the tumor had regressed.](cro-0010-0420-g01){#F1}

![**a** Histological examination with hematoxylin and eosin staining of the liver biopsy specimen showing a proliferation of tumor cells with hyperchromatic nuclei arranged in trabecular and glandular patterns. **b** The tumor cells were positive for synaptophysin. **c** The Ki-67 index was 29.1%. Original magnification for each ×100 (**a--c**).](cro-0010-0420-g02){#F2}

![The clinical course of this case. The gray boxes indicate the clinical treatment. In the lower graph, the blue line indicates serum gastrin level. Serum gastrin level decreased after administration of octreotide and S-1.](cro-0010-0420-g03){#F3}

###### 

Clinical data of the 12 pancreatic neuroendocrine neoplasms treated with S-1 (including the present case) reported in the English or Japanese literature

  No.   Author, year             Age, sex   WHO grading   Hormonal state   Metastatic site(s)   Chemotherapy including S-1   Outcome                      SSA      Treatment used prior to S-1   
  ----- ------------------------ ---------- ------------- ---------------- -------------------- ---------------------------- ---------------------------- -------- ----------------------------- -----------------------------
  1     Takeuchi et al., 2008    79, M      G3                             Nonfunctioning       Liver, lymph node, lung      S-1 + STZ                    PR       No                            Surgery
                                                                                                                                                                                                 
  2     Masuda et al., 2008      55, M      NA                             Nonfunctioning       Liver, bone                  S-1 monotherapy, S-1 + GEM   SD, SD   No                            Surgery, chemotherapy
                                                                                                                                                                                                 
  3     Nishii et al., 2008      60s, F     MANEC                          Nonfunctioning       Liver                        S-1 monotherapy              PD       No                            Surgery, TAE
                                                                                                                                                                                                 
  4     Nishimura et al., 2009   50s, F     NA                             Gastrinoma           Liver                        S-1 monotherapy              PD       Octreotide                    Surgery, TAE
                                                                                                                                                                                                 
  5     Sato et al., 2010        73, M      G2                             Nonfunctioning       Liver                        S-1 monotherapy              PR       No                            No
                                                                                                                                                                                                 
  6     Yamamoto et al., 2012    42, M      G3                             Nonfunctioning       Liver                        S-1 + GEM                    PR       No                            No
                                                                                                                                                                                                 
  7     Yoshida et al., 2013     41, F                    G3               Nonfunctioning       Liver                        S-1 + GEM                    SD       Octreotide                    No
                                                                                                                                                                                                 
  8     Kanemasa et al., 2013    63, M                    MANEC            Nonfunctioning       Liver                        S-1 monotherapy              PR       No                            No
                                                                                                                                                                                                 
  9     Yoshizawa et al., 2014   60s, F                   G2               Nonfunctioning       No (locally advanced)        S-1 monotherapy              SD       No                            No
                                                                                                                                                                                                 
  10    Yoshioka et al., 2015    69, F                    G1               Proinsulinoma        Liver, lung                  S-1 + GEM                    PD       No                            Surgery, TACE, chemotherapy
                                                                                                                                                                                                 
  11    Ikezoe et al., 2015      65, M                    G3               Somatostatinoma      Liver, lymph node            S-1 + CDDP                   NA       Octreotide                    Surgery, chemotherapy
                                                                                                                                                                                                 
  12    Present case             53, F      G2                             Gastrinoma           Liver                        S-I monotherapy              PR       Octreotide                    No

M, male; F, female; NA, not available; MANEC, mixed-adenoendocrine carcinoma; STZ, streptozocin; GEM, gemcitabine; CDDP, cisplatin; PR, partial response; PD, progressive disease; SD, stable disease; SSA, somatostatin analogues; TAE, transarterial embolization; TACE, transarterial chemoembolization.
